Biblio

Found 12 results
Filters: Author is Alumkal, Joshi J  [Clear All Filters]
2018
R. Aggarwal, Huang, J., Alumkal, J. J., Zhang, L., Feng, F. Y., Thomas, G. V., Weinstein, A. S., Friedl, V., Zhang, C., Witte, O. N., and , “Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.”, 2018.
R. Raj Aggarwal, Lloyd, P., Huang, J., Beer, T. M., Zhang, L., Thomas, G. V., True, L. D., Alumkal, J. J., Friedl, V., Weinstein, A., and , “DNA repair mutations and treatment-emergent small cell neuroendocrine prostate cancer (t-SCNC) as hallmarks of distinct subgroups of metastatic castration resistant prostate cancer (mCRPC): Data from the West Coast Prostate Cancer Dream Team.”. American Society of Clinical Oncology, 2018.
D. A. Quigley, Dang, H. X., Zhao, S. G., Lloyd, P., Aggarwal, R., Alumkal, J. J., Foye, A., Kothari, V., Perry, M. D., Bailey, A. M., and , “Genomic hallmarks and structural variation in metastatic prostate cancer”, Cell, vol. 174, pp. 758–769, 2018.
2016
E. Jay Small, Aggarwal, R. Raj, Huang, J., Sokolov, A., Zhang, L., Alumkal, J. J., Youngren, J., Ryan, C. J., Foye, A., Reiter, R. Evan, and , “Clinical and genomic characterization of metastatic small cell/neuroendocrine prostate cancer (SCNC) and intermediate atypical prostate cancer (IAC): Results from the SU2C/PCF/AACRWest Coast Prostate Cancer Dream Team (WCDT).”. American Society of Clinical Oncology, 2016.
W. Kim, Ryan, C. J., Zhang, L., Youngren, J., Wilton, J., Alumkal, J. J., Beer, T. M., Baertsch, R., Stuart, J., Chi, K. N., and , “Dehydroepiandrosterone (DHEA) in metastatic castration-resistant prostate cancer (mCRPC): Preliminary results from the SU2C/PCF/AACR West Coast Dream Team (WCDT).”. American Society of Clinical Oncology, 2016.
W. Kim, Ryan, C. J., Zhang, L., Youngren, J., Wilton, J., Alumkal, J. J., Beer, T. M., Baertsch, R., Stuart, J., Chi, K. N., and , “Dehydroepiandrosterone in metastatic castration-resistant prostate cancer: Preliminary results from the SU2C-PCF West Coast Dream Team (WCDT).”. American Society of Clinical Oncology, 2016.
R. Raj Aggarwal, Youngren, J., Sokolov, A., Huang, J., Thomas, G. V., True, L. D., Foye, A., Alumkal, J. J., Ryan, C. J., Beer, T. M., and , “Persistence of AR signaling in small cell neuroendocrine prostate cancer (SCNC) and intermediate atypical carcinoma (IAC): Results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).”. American Society of Clinical Oncology, 2016.
R. Aggarwal, Beer, T. M., Gleave, M., Stuart, J. M., Rettig, M., Evans, C. P., Youngren, J., Alumkal, J. J., Huang, J., Thomas, G., and , “Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation–Supported West Coast Prostate Cancer Dream Team”, European urology focus, vol. 2, pp. 469–471, 2016.
2015
E. Jay Small, Huang, J., Youngren, J., Sokolov, A., Aggarwal, R. Raj, Thomas, G., True, L. D., Zhang, L., Foye, A., Alumkal, J. J., and , “Characterization of neuroendocrine prostate cancer (NEPC) in patients with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) or enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer ”. American Society of Clinical Oncology, 2015.
2014
E. Jay Small, Youngren, J., Thomas, G., Olson, S., Toschi, A., Foye, A., Alumkal, J. J., Rettig, M., Gleave, M. Edwin, Evans, C. P., and , “Androgen receptor (AR) amplification in patients with metastatic castration-resistant prostate cancer (mCRPC) refractory to therapy with abiraterone acetate or enzalutamide: Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team ”. American Society of Clinical Oncology, 2014.
J. J. Alumkal, Heiser, L., Beer, T. M., Small, E. Jay, Baertsch, R., Stuart, J., King, C., Korkola, J., Cetnar, J., Graff, J. Nicole, and , “Identifying enzalutamide resistance mechanisms in men with castration-resistant prostate cancer.”. American Society of Clinical Oncology, 2014.
E. Jay Small, Youngren, J., Beer, T. M., Ryan, C. J., Thomas, G., Pourmand, N., Reiter, R. Evan, Alumkal, J. J., Stuart, J. M., Evans, C. P., and , “The molecular and pathway characterization of patients with metastatic castration resistant prostate cancer (mCRPC) refractory to therapy with abiraterone acetate or enzalutamide: Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream”. American Society of Clinical Oncology, 2014.